FibroBiologics Announces Promising IND-Enabling Updates for Fibroblast Spheroids in Psoriasis Treatment
Reuters
Sep 11
<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Announces Promising IND-Enabling Updates for Fibroblast Spheroids in Psoriasis Treatment
FibroBiologics, Inc., a clinical-stage biotechnology company, has announced positive updates from its psoriasis research program. The company reported favorable IND-enabling results demonstrating the potential of human dermal fibroblast (HDF) spheroids as a therapeutic approach for chronic-relapse psoriasis. Currently, FibroBiologics is expanding its research efforts by exploring repeated dosing regimens and conducting systemic and local cytokine profiling, along with histopathological assessments of skin lesions. These studies aim to deepen the understanding of the underlying mechanisms and strengthen the clinical foundation for further advancement. The results from these studies have been presented and mark a pivotal milestone in the company's path toward developing treatments for chronic inflammatory diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527153-en) on September 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.